Financial Contrast: BioRestorative Therapies (NASDAQ:BRTX) versus Global Cord Blood (NYSE:CORBF)

BioRestorative Therapies (NASDAQ:BRTX) and Global Cord Blood (NYSE:CORBF) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, profitability, risk, dividends and earnings.

Valuation and Earnings

This table compares BioRestorative Therapies and Global Cord Blood’s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioRestorative Therapies	$145,800.00	57.58	-$14.41 million	($3.51)	-0.35
Global Cord Blood	$196.12 million	N/A	$79.04 million	N/A	N/A

Global Cord Blood has higher revenue and earnings than BioRestorative Therapies.

Profitability

This table compares BioRestorative Therapies and Global Cord Blood’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
BioRestorative Therapies	-9,873.97%	-114.84%	-107.19%
Global Cord Blood	N/A	N/A	N/A

Analyst Recommendations

This is a summary of current ratings and recommmendations for BioRestorative Therapies and Global Cord Blood, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioRestorative Therapies	0	0	0	0	N/A
Global Cord Blood	0	0	0	0	N/A

Insider & Institutional Ownership

69.4% of BioRestorative Therapies shares are held by institutional investors. 21.6% of BioRestorative Therapies shares are held by insiders. Comparatively, 0.5% of Global Cord Blood shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Volatility and Risk

BioRestorative Therapies has a beta of 61.51, indicating that its share price is 6,051% more volatile than the S&P 500. Comparatively, Global Cord Blood has a beta of -0.25, indicating that its share price is 125% less volatile than the S&P 500.

Summary

Global Cord Blood beats BioRestorative Therapies on 5 of the 8 factors compared between the two stocks.

About BioRestorative Therapies

BioRestorative Therapies, Inc., a life sciences company, focuses on the development of regenerative medicine products and therapies using cell and tissue protocols primarily involving adult stem cells. The company's two core developmental programs relate to the treatment of disc/spine disease and metabolic disorders. Its disc/spine program (brtxDisc) includes a lead cell therapy candidate, BRTX-100, a product candidate formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow, which has completed Phase 1 clinical trials for use in the non-surgical treatment of painful lumbosacral disc disorders. The company is also developing Metabolic Program (ThermoStem), a cell-based therapy candidate that is in preclinical stage to target obesity and metabolic disorders using brown adipose derived stem cells to generate brown adipose tissue. In addition, it provides investigational curved needle device designed to deliver cells and/or other therapeutic products or material to the spine and discs. BioRestorative Therapies, Inc. has a research and development agreement with Rohto Pharmaceutical Co., Ltd.; a research agreement with Pfizer, Inc.; and a research collaboration agreement with the University of Pennsylvania. The company was formerly known as Stem Cell Assurance, Inc. and changed its name to BioRestorative Therapies, Inc. in August 2011. The company was incorporated in 1997 and is based in Melville, New York.

About Global Cord Blood

Global Cord Blood Corporation, together with its subsidiaries, provides umbilical cord blood storage and ancillary services in the People's Republic of China. The company offers cord blood testing, processing, and storage services under the direction of subscribers; and tests, processes, and stores donated cord blood, as well as provides matching services. As of March 31, 2022, it operated three cord blood banks, including one in the Beijing municipality; one in the Guangdong province; and one in the Zhejiang province. The company was formerly known as China Cord Blood Corporation and changed its name to Global Cord Blood Corporation in March 2018. Global Cord Blood Corporation is based in Central, Hong Kong. Global Cord Blood Corporation operates as a subsidiary of Blue Ocean Structure Investment Company Ltd.